coronary artery disease
For every 20/10 mmHg increase in blood pressure (BP), there is a lifetime doubling of mortality related to ischemic heart disease or cerebrovascular accident. As with all other associated complications and comorbid diseases, aggressive BP control, along with therapy specific for the individual condition, may retard the progression of disease.
The risk of developing cerebrovascular accident (CVA) varies linearly with blood pressure (BP), and BP control reduces the risk of recurrent CVA.
left ventricular hypertrophy
Left ventricular hypertrophy (LVH) on echocardiography is seen in more than 30% of hypertensive patients.
congestive heart failure
Patients with hypertension are 3 times more likely to develop congestive heart failure (systolic or diastolic dysfunction) as are normotensive patients.
ACE inhibitors, angiotensin-II receptor antagonists, and beta-blockers confer a mortality benefit. Diuretics do not, but loop diuretics are frequently used to relieve symptoms of fluid overload.
Blockade of aldosterone has been associated with decreased end-organ fibrosis.
Hypertension is associated independently with retinopathy.
Hypertension is also a major risk factor for development of other retinal vascular diseases, such as retinal vein or artery occlusion, or ischemic optic neuropathy.
peripheral artery disease
Treatment of hypertension in patients with peripheral artery disease reduces the risk of myocardial infarction, stroke, or congestive heart failure.
chronic kidney disease
Hypertension is closely associated with the development of renal disease and end-stage renal disease (ESRD). However, while many hypertensive patients will develop a mild degree of nephrosclerosis, few progress to ESRD.
A more malignant course of hypertensive kidney disease is seen in black than in white people.
More than 70% of patients with aortic dissection have a history of hypertension.
Undiagnosed or inadequately treated essential hypertension is the most common cause of hypertensive emergency.
Use of this content is subject to our disclaimer